Mutated EGFR-IN-1

Mutated EGFR-IN-1 is a high-purity pharmaceutical-intermediates supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.

Mutated EGFR-IN-1 is used as a chemical scaffold in research and drug development focused on inhibitors targeting mutant forms of the epidermal growth factor receptor (EGFR). It is particularly relevant for studying activating mutations such as L858R, Exon 19 deletions, and the T790M resistance mutation. The compound is applied in biochemical and cellular assays to evaluate inhibition potency, selectivity, and structure–activity relationships of EGFR-targeting compounds. It is also used in preclinical studies to model how molecular modifications influence binding affinity, inhibition kinetics, and resistance profiles. Its solubility in DMSO allows it to be prepared at defined concentrations for in vitro assays, supporting reproducible experimental setups.

Mutated EGFR-IN-1 offers a reliable starting point for designing inhibitors with high specificity against mutant EGFR variants. Its well-defined chemical structure and solubility facilitate reproducible assays and experimental consistency. By focusing on mutant EGFR rather than wild-type, it enables the development of compounds with improved selectivity, potentially reducing off-target effects. Its chemical scaffold allows flexibility for structural modifications to optimize potency, resistance profiles, and pharmacokinetic properties in preclinical studies. These characteristics make it a valuable tool in early-stage drug discovery targeting EGFR-driven cancers.

Mutated EGFR-IN-1 is a specialized research compound used to support the development of inhibitors targeting mutant EGFR variants. Its defined chemical properties, solubility, and scaffold versatility allow precise evaluation of inhibition, structure–activity relationships, and resistance mechanisms. Overall, it is a practical and important tool in preclinical research for exploring next-generation EGFR-targeted therapies.

Previous

Ethyl 4-bromobutyrate丨CAS 2969-81-5

Next

Ammonium 1-pyrrolidinedithiocarbamate丨CAS 5108-96-3